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PathologyAlzheimer's disease (AD) is the most common neurodegenerative disorder worldwide, but its etiology is still not
completely understood. The identiﬁcation of underlying pathological mechanisms is becoming increasingly
important for the discovery of biomarkers and therapies, for which metabolomics presents a great potential. In
this work, we studied metabolic alterations in different brain regions of the APP/PS1 mice by using a high-
throughput metabolomic approach based on the combination of gas chromatography–mass spectrometry and
ultra-high performance liquid chromatography–mass spectrometry. Multivariate statistics showed that
metabolomic perturbations arewidespread, affectingmainly the hippocampus and the cortex, but are also present
in regions not primarily associated with AD such as the striatum, cerebellum and olfactory bulbs. Multiple meta-
bolic pathways could be linked to the development of AD-type disorders in thismousemodel, including abnormal
purine metabolism, bioenergetic failures, dyshomeostasis of amino acids and disturbances in membrane lipids,
among others. Interestingly, region-speciﬁc alterationswere observed for someof the potentialmarkers identiﬁed,
associatedwith abnormal fatty acid composition of phospholipids and sphingomyelins, or differential regulation of
neurotransmitter amino acids (e.g. glutamate, glycine, serine, N-acetyl-aspartate), not previously described to our
knowledge. Therefore, these ﬁndings could provide a new insight into brain pathology in Alzheimer's disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common neurodegenerative
disorder amongolder people, which involves a progressive loss ofmem-
ory and cognitive abilities leading to dementia. Deposition of senile
plaques containing β-amyloid peptides and formation of neuﬁbrillary
tangles are the twomajor hallmarks of AD [58], but other profound bio-
chemical alterations also occur in the AD brain, including oxidativeomatography–massspectrome-
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cía-Barrera), vitorica@us.esstress, mitochondrial, dysfunction, inﬂammation, membrane lipid dys-
regulation and neurotransmitter disruption, among others [37,46,48].
These pathological lesions are mainly localized in medial temporal
lobe structures, speciﬁcally the cortex and the hippocampus [6], con-
tributing to neuronal degeneration, loss of synapses, and brain atrophy.
However, it has been demonstrated that perturbations are more wide-
spread and affect a variety of sites such as the cerebellum [5], brainstem
[59] or the olfactory system [63]. Neuroimaging techniques have been
extensively applied for in vivo detection of neuropathological features
in ADpatients, includingmagnetic resonance imaging (MRI) tomeasure
structural and functional changes of brain [41], positron emission to-
mography (PET) for detection of amyloid plaques [55] and changes in
glucose metabolism [49], and magnetic resonance spectroscopy (MRS)
to quantify metabolite markers [35]. On the other hand, metabolomic
analysis is gaining great importance for the discovery of novel potential
biomarkers for diagnosis and the elucidation of underlying mecha-
nisms. Metabolomics, based on the comprehensive and simultaneous
analyses of multiple metabolites in biological samples, presents a great
potential in health survey for the study of disease pathology, discovery
of biomarkers and drug development because metabolites represent
the end point of biological reactions, reﬂecting well the interactions
2396 R. González-Domínguez et al. / Biochimica et Biophysica Acta 1842 (2014) 2395–2402between genes, proteins and the environment [44]. Thereby, several
metabolomic studies have been performed in the last years for the
investigation of AD [30]. Most of these studies have been performed in
bioﬂuids due to the difﬁcult availability of human brain tissue, and be-
cause the use of postmortem tissues supposes that disease is at its end
stage. Thus, only a fewpreliminary studies have been previously report-
ed in this subject [4,21,31], demonstrating the potential of this approach
although it requires further investigation with larger and better charac-
terized patient cohorts. Alternatively, numerous transgenic animal
models have been developed for studying AD pathophysiology [23],
fromwhich brain samples can be obtained at different stages of disease.
Forster et al. used the TASTPM transgenic mice to investigate brain lon-
gitudinal metabolic differences by protonmagnetic resonance spectros-
copy, and found signiﬁcant differences in levels of metabolites such as
myo-inositol, succinate, glycerophosphocholine and choline [16]. In
other studies, the metabolic proﬁles of both brain and plasma from dif-
ferent mouse models were characterized and compared to those from
wild-type mice [22,29]. Lower levels of metabolites were found in plas-
ma samples, and they ﬂuctuate more between the two groups than
brain metabolites. However, the statistical models built using plasma
metabolite proﬁles were more accurate than the brain tissue despite
the smaller number of factors. Furthermore, the role of a dysregulated
endocannabinoid–eicosanoid network in the pathogenesis of AD has
been recently demonstrated in the APP/PS1 mice with inactivated
monoacylglycerol lipase [52]. On the other hand, other studies focused
on individual brain areas including the hippocampus [42,65,72], cortex
[11] and cerebellum [1,43], becausemetabolic perturbations induced by
AD-type disorders could be region-speciﬁc in the brain. In this sense, the
characterization of regional metabolomic perturbations may be of
greater interest in order to investigate the impact of disease on different
brain regions and determine the most affected ones in AD mice. Only a
few authors have previously performed a comparative metabolomic in-
vestigation in different brain areas, by using in vitro nuclear magnetic
resonance [38,56,73]. These ﬁndings demonstrated that the hippocam-
pus and the cortex are the most sensitive regions during early-stage
AD, but perturbations in metabolism also affect other tissues such as
cerebellum and midbrain. However, limited metabolic information was
obtained considering the total number of discriminant metabolites
detected (N-acetylaspartate, myoinositol, glutamate, GABA, creatine,
taurine, and a fewothers), because of the low sensitivity of this approach.
For this reason, the application of high-throughput metabolomic ap-
proach based on mass spectrometry could be of great interest in order
to delve into metabolic alterations associated with Alzheimer's disease
occurring in different brain regions.
In this study, a metabolomic platform based on complementary
analysis by gas chromatography–mass spectrometry (GC–MS) and
reversed-phase ultra-high performance liquid chromatography–mass
spectrometry (UPLC–MS) was used to investigate metabolic perturba-
tions in ﬁve brain regions of the APP/PS1 transgenicmice of Alzheimer's
disease, including cortex, hippocampus, striatum, cerebellum and olfac-
tory bulbs. This mouse model is extensively employed in AD research
given that it reproduces well some of the neuropathological and cogni-
tive deﬁcits observed in human Alzheimer, with a phenotype character-
ized by deposition of Aβ plaques starting from the age of four months,
glial activation, and deﬁcits in cognitive functions at the age of 6 months
[47]. Furthermore, the application of this multiplatform approach using
two complementary methods allowed the extension of the analytical
coverage of endogenous metabolites present in brain samples com-
pared with conventional procedures based on NMR. Thereby, while
GC–MS provides high-chromatographic resolution for the primary low
molecular weight metabolites, reversed phase liquid chromatography
can be considered as the standard tool for the separation of medium
polar and non-polar analytes. Multivariate statistics was used to dis-
criminate metabolic proﬁles from transgenic animals and wild-type
controls, and thus numerous metabolites could be identiﬁed as poten-
tial markers of disease. These ﬁndings indicated that all brain regionsanalyzed are affected to a greater or lesser extent, but in addition it is
noteworthy that some of these metabolic alterations could be region-
speciﬁc.
2. Materials and methods
2.1. Animal handling
Transgenic APP/PS1 mice (C57BL/6 background) were generated as
previously described by Jankowsky et al., expressing the Swedishmuta-
tion of APP together with PS1 deleted in exon 9 [32]. On the other hand,
age-matchedwild-typemice of the same genetic background (C57BL/6)
were purchased from Charles River Laboratory for their use as controls
(WT). In this study, male and female animals at 6 months of age were
used for experiments (TG: N = 30, male/female 13/17; WT: N = 30,
male/female 15/15). Animals were acclimated for 3 days after reception
in rooms with a 12-h light/dark cycle at 20–25 °C, with water and food
available ad libitum. Then,micewere anesthetized by isoﬂurane inhala-
tion and sacriﬁced by exsanguination via cardiac puncture. Brains were
rapidly removed, rinsed with saline solution (0.9% NaCl w/v) and dis-
sected into the hippocampus, cortex, striatum, cerebellum and olfactory
bulbs. Finally, tissues were transferred to individual Eppendorf tubes,
snap-frozen in liquid nitrogen and stored at−80 °C until analysis. Ani-
mals were handled according to the directive 2010/63/EU stipulated by
the European Community, and the study was approved by the Ethical
Committee of University of Huelva.
2.2. Sample preparation
Large brain regions (cortex and cerebellum) were cryo-homogenized
using a cryogenic homogenizer SPEX SamplePrep (Freezer/Mills 6770),
during 30 s at a rate of 10 strokes per second. Subsequently, tissues
were extracted with pre-cooled 0.1% formic acid in methanol
(−20 °C) using a pellet mixer for cell disruption (VWR International,
UK). For this, tissue samples were exactly weighed in Eppendorf tubes
(30 mg for homogenized tissues, and the entire organ for smaller tis-
sues) and mixed with the extraction solvent (10 μl/mg). The mixture
was homogenized during 2 min in an ice bath, and then centrifuged at
10,000 g for 10 min at 4 °C. An aliquot of the supernatant (50 μl) was
split for derivatization before GC–MS ﬁngerprinting, and the rest of
the sample was transferred to the injection vial for UPLC–MS analysis.
Derivatization was carried out according to a two-step methodology
previously described [2]. For this, 50 μl of extracts was dried under ni-
trogen stream and redissolved in 50 μl of 20 mg ml−1 methoxyamine
in pyridine for protection of carbonyl groups by methoximation. After
brieﬂy vortexing, samples were incubated at 80 °C for 15 min in a
water bath. Then silylation was performed by adding 50 μl of MSTFA
and incubating it at 80 °C for a further 15min. Finally, extractswere cen-
trifuged at 4000 g for 1 min and the supernatant was collected for anal-
ysis. Furthermore, quality control (QC) samples were prepared by
pooling equal volumes of each sample, which allows the monitoring
of the stability and performance of the system along the analysis period
[57].
2.3. Metabolomic analysis by GC–MS
Analyses were performed in a Trace GC ULTRA gas chromato-
graph coupled to an ion trap mass spectrometer detector ITQ 900
(Thermo Fisher Scientiﬁc), using a Factor Four capillary column VF-
5MS 30 m × 0.25 mm ID, with 0.25 μm of ﬁlm thickness (Varian).
The GC column temperature was set to 100 °C for 0.5 min, and pro-
grammed to reach 320 °C at a rate of 15 °C per minute. Finally, this
temperature was maintained for the other 2.8 min, being that the
total time of analysis was 18 min. The injector temperature was kept
at 280 °C, and helium was used as carrier gas at a constant ﬂow rate
of 1 mlmin−1. For mass spectrometry detection, ionization was carried
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temperature was set at 200 °C. Data were obtained acquiring full scan
spectra in the m/z range 35–650. For analysis, 1 μl of the sample is
injected in a splitless mode.
2.4. Metabolomic analysis by UPLC–MS
Samples were ﬁngerprinted by ultra performance liquid chroma-
tography (Accela LC System, Thermo Fisher Scientiﬁc) coupled to a
quadrupole-time-of-ﬂight mass spectrometry system equipped an with
electrospray source (QSTAR XL Hybrid System, Applied Biosystems).
Chromatographic separations were performed in a reversed-phase col-
umn (Hypersil Gold C18, 2.1 × 50 mm, 1.9 μm) thermostated at 50 °C,
with an injection volume of 5 μl. Solvents were delivered at a ﬂow rate
0.5 ml/min, using methanol (solvent A) and water (solvent B), both con-
taining 10 mM ammonium formate and 0.1% formic acid. The gradient
elution program was: 0–1 min, 95% B; 2.5 min, 25% B; 8.5–10 min, 0% B;
and 10.1–12 min, 95% B. MS operated in positive and negative polarities,
acquiring full scan spectra in the m/z range of 50–1000 with 1.005 s scan
time. The ion spray voltage (IS)was set at 5000V and−2500V, andhigh-
purity nitrogenwas used as curtain, nebulizer and heater gas at ﬂow rates
of about 1.48 l min−1, 1.56 l min−1 and 6.25 l min−1, respectively. The
source temperature was ﬁxed at 400 °C, with a declustering potential
(DP) of 100 V/–120V, and a focusing potential (FP) of±350V. To acquire
MS/MS spectra, nitrogen was used as collision gas.
2.5. Data pre-processing
Raw data was processed following the pipeline described by
Katajamaa and Oresic, which proceeds through multiple stages includ-
ing feature detection, alignment of peaks and normalization [36]. For
this purpose, we employed the freely available software XCMS, included
in the R platform (http://www.r-project.org). UPLC–MS ﬁles were con-
verted into mzXML format using the msConvert tool (ProteoWizard),
while GC–MS ﬁles were converted into netCDF using the Thermo File
Converter tool (Thermo Fisher Scientiﬁc). Subsequently, data were
extracted using the matchedFilter method. This algorithm slices data
into extracted ion chromatograms (XIC) on a ﬁxed step size (default
0.1 m/z), and then each slice is ﬁltered with matched ﬁltration using a
second-derivative Gaussian as the model peak shape [61]. The XCMS
parameters were optimized according to the characteristics of data
sets obtained in order to extract the maximum information as possible.
Finally, the settings applied for UPLC–MS datawere S/N threshold 2 and
full width at half-maximum (fwhm) 10, while for GC–MS data the
fwhm was set at 3. After peak extraction, grouping and retention time
correction of peaks (alignment) were accomplished in three iterative
cycles with descending bandwidth (bw) from 10 to 1 s in UPLC–MS,
and descending bw from 5 to 1 s for GC–MS. Then, imputation of miss-
ing values was performed by returning to the raw spectral data and
integrating the areas of the missing peaks which are below the applied
signal-to-noise ratio threshold, using the ﬁllPeaks algorithm. For data
normalization, the locallyweighted scatter plot smoothing (LOESS) nor-
malization method was used, which adjusts the local median of log fold
changes of peak intensities between samples in the data set to be
approximately zero across the whole peak intensity range [68]. Finally,
the data were submitted to logarithmic transformation, in order to
stabilize the variance of results. The pre-processed data were then
exported as a .csv ﬁle for further data analysis by multivariate
procedures.
2.6. Multivariate statistics
The data were subjected to multivariate analysis by principal com-
ponent analysis (PCA) and partial least squares discriminant analysis
(PLS-DA) in order to compare metabolomic proﬁles obtained, using
the SIMCA-P™ software (version 11.5, UMetrics AB, Umeå, Sweden).Before performing statistical analysis, data was submitted to Pareto
scaling for reducing the relative importance of larger values [66]. The
quality of the models was assessed by the R2 and Q2 values, supplied
by the software, which provide information about the class separation
and predictive power of the model, respectively. These parameters are
ranged between 0 and 1, and they indicate the variance explained by
the model for all the data analyzed (R2) and this variance in a test set
by cross-validation (Q2). Finally, potential biomarkers were selected ac-
cording to the Variable Importance in the Projection, or VIP (aweighted
sumof squares of the PLSweight, which indicates the importance of the
variable in the model), considering only variables with VIP values
higher than 1.5, indicative of signiﬁcant differences among groups. Fur-
thermore, these metabolites were validated by t-test with Bonferroni
correction for multiple testing (p-values below 0.05), using the
STATISTICA 8.0 software (StatSoft, Tulsa, USA).
2.7. Metabolite identiﬁcation
Discriminant metabolites detected by GC–MS were identiﬁed using
the NIST Mass Spectral Library (version 08), considering only those
variables with a similarity index (SI) greater than 70%. Alternatively,
the identiﬁcation of metabolites from UPLC–MS proﬁling was made
matching the experimental accurate mass and tandem mass spectra
(MS/MS) with those available in metabolomic databases (HMDB,
METLIN and LIPIDMAPS). Furthermore, the identity of lipids was
conﬁrmed based on characteristic fragmentation patterns previously
described. Phosphatidylcholines (PCs) and lysophosphatidylcholines
(LPCs) presented characteristic ions in positive ionization mode at m/z
184, 104 and 86, and two typical fragments due to the loss of
trimethylamine (m/z 59) and phosphocholine (m/z 183). In contrast,
the product-ion spectra of ethanolamines and serines were dominated
by [M+H−141]+ and [M + H−185]+ respectively, arising from the
elimination of the phosphoethanolamine or phosphoserine moiety.
Finally, in negative mode these distinctive signals were found at 168,
196, 241, 171 and [M−H−87]−, for choline, ethanolamine, inositol,
glycerol and serine derived lipids, respectively [53]. Furthermore, the
fragmentation in the glycerol backbone and release of the fatty acyl sub-
stituents enabled the identiﬁcation of individual species of phospho-
lipids, as previously described [70]. For sphingomyelins, typical
product ions appear at m/z 264 and 282 due to the fragmentation in
the sphingosine moiety, and the cleavage of phosphocholine head
group generates characteristic fragments at 184 and 168m/z, in positive
and negative modes respectively [27].
3. Results
Metabolomic proﬁles corresponding to transgenic animals, wild-
type controls and quality control samples were aligned together to
perform sample classiﬁcation by multivariate data analysis. An initial
principal component analysis (PCA) plot was generated with data
from each brain region using the different techniques (UPLC–ESI(+)/
MS, UPLC–ESI(−)/MS, GC–MS) in order to check trends, outliers and
quality of the analysis, and to ensure grouping of the QC samples. A
good clustering of quality control samples was observed in the score
plot (Fig. 1a, for the hippocampus), indicative of stability during the
analyses [57], without signiﬁcant outliers according to the Hotelling
T2-range plot (not shown). Partial least squares discriminant analysis
(PLS-DA) was used in the same data sets to obtain a perfect separation
of the different study groups (Fig. 1b, for the hippocampus). These
models yielded satisfactory values for the quality parameters R2 and
Q2, with a variance explained close to 100% and variance predicted
above 60% for all models (Table 1).
Discriminant metabolites were then selected according to the VIP
value for each PLS-DA model (Tables 2–4). Major changes were
observed in amino acids and related compounds, nucleotides, and
other low molecular weight metabolites (Table 2), lysophospholipids
Fig. 1. Score plots of PCA (a) and PLS-DA (b) models for the hippocampus.
Table 2
Low molecular weight metabolites identiﬁed as potential markers for discrimination
between APP/PS1 and control mice. HP, hippocampus; CT, cortex; ST, striatum; CB, cere-
bellum; OB, olfactory bulb. NS: non signiﬁcant change.
Metabolite RT (min)⁎ Fold change
HP CT ST CB OB
Amino acids
Glycine 4.42a, 0.28b 0.72 0.62 0.74 1.47 NS
Serine 4.72a, 0.28b 1.21 NS 1.35 NS NS
Threonine 4.95a 0.66 NS NS NS NS
Aspartate 6.07a 0.54 0.46 NS NS 0.69
Pyroglutamate 6.28a, 0.28b 0.75 0.67 0.85 2.11 NS
Glutamate 6.95a, 0.28b 0.46 0.72 1.46 1.49 0.62
N-acetylaspartate 7.18a 0.75 0.46 1.58 1.22 0.72
Valine 0.28b 1.14 1.07 1.10 NS NS
Histidine 0.28b NS 0.71 NS NS NS
Taurine 0.28b 0.92 0.92 0.73 0.85 NS
Nucleotides
Adenine 0.32b 0.70 0.90 NS NS NS
Hypoxanthine 8.47a, 0.40b 1.41 1.46 1.46 1.53 NS
Xanthine 9.85a 1.48 1.79 1.46 NS NS
Inosine 13.05a, 0.42b 1.78 1.76 2.24 2.23 NS
Adenosine 13.38a 1.21 1.35 NS 1.67 NS
Guanosine 14.02a 1.24 1.24 1.58 1.47 NS
AMP 0.36b 0.80 0.89 0.82 NS NS
cAMP 0.36b 0.79 0.84 0.82 NS NS
cGMP 0.36b 0.87 NS NS NS NS
UMP 0.36b 0.88 NS NS NS NS
Phosphoribosyl-AMP 0.36b 0.91 0.89 0.82 NS NS
Others
Lactic acid 2.70a 0.76 0.67 0.90 0.63 0.58
Urea 3.97a 0.38 0.60 0.70 0.58 0.42
Glycerol 4.08a 1.52 1.41 2.06 1.77 NS
Malic acid 5.88a 0.78 0.65 NS NS NS
Creatinine 6.38a 0.53 0.59 0.67 0.67 0.66
2-Hydroxyglutarate 6.58a NS 0.69 NS 0.58 NS
Pyrophosphate 7.08a 0.84 NS NS NS NS
Ethanolamine 7.38a 0.53 0.45 0.69 0.82 0.48
Glycerol-3-phosphate 7.97a 1.39 1.84 1.43 1.38 NS
Citric acid 8.39a 0.45 0.61 0.69 0.73 NS
Myoinositol 10.22a 2.11 1.37 1.82 2.07 1.34
Glucose-6-phosphate 10.93a 0.67 NS NS NS NS
Cholesterol 16.47a 0.25 0.49 0.43 0.23 0.35
Choline 0.28b 1.25 1.30 1.28 NS NS
Phosphocholine 0.28b 1.16 1.25 1.30 1.13 NS
Glycerophosphocholine 0.28b 1.17 1.28 1.41 1.18 NS
Dopamine 0.28b 0.94 NS 0.83 NS NS
b
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ations were found in the hippocampus and in the cortex, but several
impairments were also present in the cerebellum, striatum and olfactory
bulbs. Moreover, it is noteworthy to mention that some metabolites
showed opposite trends in different brain areas, suggesting that region-
speciﬁc perturbations might occur. Therefore, the characterization of
regional metabolic abnormalities in the brain of the APP/PS1 mice might
provide an interesting insight into the pathological mechanisms associat-
ed with the development and spread of disease in the brain.Lactose 0.33 1.18 NS NS NS NS
⁎ Retention times formetabolites detected by GC/MSa and/or UPLC/MSb. Abbreviations:
AMP, adenosine monophosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic
guanosine monophosphate; and UMP, uridine monophosphate.4. Discussion
A metabolomic platform based on the combination of gas chroma-
tography–mass spectrometry and reversed-phase ultra-high perfor-
mance liquid chromatography–mass spectrometry was used to study
regional metabolic abnormalities in the brain of 6 month-old APP/PS1
transgenic mice. This mouse model, co-expressing mutated amyloid
precursor protein and deleted presenilin 1, exhibits accelerated ADTable 1
Statistical parameters of PLS-DA models for the hippocampus (HP), cortex (CT), striatum
(ST), cerebellum (CB), and olfactory bulb (OB). A: number of latent components; R2:
variance explained; Q2: variance predicted.
HP CT ST CB OB
GC/MS A 4 4 3 3 3
R2 0.997 0.992 0.991 0.996 0.998
Q2 0.735 0.719 0.69 0.61 0.722
UPLC–ESI(+)/MS A 4 4 5 5 6
R2 0.992 0.99 0.95 0.995 0.992
Q2 0.922 0.924 0.788 0.944 0.89
UPLC–ESI(−)/MS A 5 4 6 6 7
R2 0.991 0.983 0.981 0.992 0.988
Q2 0.877 0.794 0.8 0.844 0.862phenotype characterized by amyloid deposits and behavioral deﬁcits
[47]. Furthermore, the study of the neurochemical proﬁle and age-
dependent metabolic changes exhibited by the transgenic APP/PS1
mice has demonstrated that these alterations precede cognitive dys-
functions [9], being very similar to those found in human Alzheimer's
disease. Therefore, the characterization of region-speciﬁc metabolic
abnormalities in this model might aid in the investigation of the patho-
logical mechanisms associated with AD.
Purine metabolism has been repeatedly associated with neurode-
generative mechanisms occurring in Alzheimer's disease, which is in
accordance with ourmetabolomic ﬁndings (Table 2). The hippocampus
was the most affected region, but these metabolic changes were also
observed in other areas such as the cortex, striatum and cerebellum
(in this order). Cyclic nucleotides, cyclic adenosine monophosphate
(cAMP) and cyclic guanosinemonophosphate (cGMP), are secondmes-
sengers associated with neuroplasticity and neuroprotection, which
have been suggested to be affected in AD. Phosphodiesterases, enzymes
responsible for the breakdown of cyclic nucleotides, appear to be over-
expressed in AD brains [3], together with a perturbation of cAMP/PKA
[40] and NO/cGMP [12] signaling pathways, supporting the decrease
Table 3
Lysophospholipids identiﬁed as potential markers for discrimination between APP/PS1
and control mice. HP, hippocampus; CT, cortex; ST, striatum; CB, cerebellum; OB, olfactory
bulb. NS: non-signiﬁcant change.
Metabolite RT (min) Fold change
HP CT ST CB OB
LPI(20:4) 4.07 1.56 1.60 1.67 NS NS
LPE(22:6) 4.28 1.62 1.63 1.57 1.59 1.66
LPE(20:4) 4.28 1.79 1.72 1.35 NS 1.81
LPI(16:0) 4.32 1.53 NS NS NS NS
LPC(22:6) 4.47 1.53 1.45 NS NS 1.56
LPC(20:4) 4.47 1.46 1.61 1.61 NS 1.58
LPI(18:0) 4.87 1.62 1.84 NS 1.84 1.71
LPC(18:1) 4.88 1.54 1.38 NS NS 1.61
LPI(20:1) 4.88 1.41 NS NS NS NS
LPC(16:0) 4.93 1.28 1.36 1.67 NS NS
LPE(18:0) 5.22 NS 1.49 NS NS NS
LPC(18:0) 5.67 1.36 1.56 1.74 1.56 NS
Abbreviations: LPI, lysophosphoinositol; LPE, lysophosphoethanolamine; and LPC,
lysophosphocholine.
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reduced levels of adenosine monophosphate (AMP) could be related
to accelerated degradation due to elevated activity of adenosine
monophosphate deaminase in the brain, provoking over-production of
ammonia leading to hyperammonemia [60]. This decrease of AMP levels
may have important consequences in cellular energy homeostasis,
given that it plays a central role in glucose and lipidmetabolism through
the AMP-activated protein kinase (AMPK), which is known to be de-
creased in the AD brain [7]. Concentrations of nucleosides (adenosine,
guanosine, inosine) tended to be higher in the brains from APP/PS1
mice, whichmight suggest a disturbed neuroprotective function leading
to neural damage because purine nucleosides exert important
neuromodulator roles in the central nervous system [64]. In addition,Table 4
Phospholipids and sphingomyelins identiﬁed as potential markers for discrimination between
olfactory bulb. NS: non signiﬁcant change.
Metabolite RT (min) Fold change
HP CT ST CB OB
Decreased phospholipids
PC(18:3/22:6) 8.40 NS 0.67 0.66 NS NS
PC(18:1/22:6) 8.46 NS 0.71 0.63 NS 0.66
PC(18:0/22:6) 8.47 0.67 0.74 0.59 0.70 NS
PE(22:6/22:6) 7.68 0.68 NS NS NS 0.61
PE(16:1/20:4) 7.70 0.62 0.77 0.74 0.74 NS
PE(20:4/22:6) 7.73 0.68 NS NS NS 0.62
PE(18:3/22:6) 7.97 NS 0.65 NS NS NS
PE(16:0/22:6) 7.97 NS 0.73 NS 0.73 0.66
PE(16:1/18:1) 8.02 0.70 NS NS 0.75 NS
PE(18:1/20:4) 8.10 0.71 NS NS NS 0.64
PE(16:0/18:1) 8.31 0.65 NS NS 0.73 NS
PE(18:1/18:1) 8.40 0.63 0.66 0.70 0.77 0.72
PE(18:1/18:0) 8.66 0.72 NS NS NS NS
PPE(18:1/16:1) 8.20 0.62 0.66 NS NS NS
PPE(18:1/20:4) 8.25 0.72 0.74 NS NS NS
PPE(18:1/22:6) 8.25 NS 0.77 NS NS 0.64
PPE(18:1/16:0) 8.49 0.68 NS NS NS NS
PPE(18:1/18:1) 8.58 0.58 0.61 NS NS 0.61
PPE(18:0/18:1) 8.85 0.70 0.72 NS 0.72 NS
PPE(18:1/20:1) 8.92 0.71 NS NS NS NS
PS(22:6/22:6) 7.35 0.71 0.77 0.63 NS NS
PS(20:4/22:6) 7.40 0.50 NS NS NS NS
PS(18:1/22:6) 7.74 0.67 NS 0.60 NS NS
PI(16:0/22:6) 7.51 NS 0.78 NS NS NS
PI(18:1/18:0) 8.22 0.68 NS NS NS NS
PG(16:1/22:6) 7.35 0.73 0.68 NS NS NS
SM(d18:1/18:1) 8.38 0.67 NS NS NS NS
SM(d18:1/23:1) 9.55 0.63 0.69 NS 0.69 0.60
SM(d18:1/24:1) 9.76 0.62 0.58 0.67 0.62 0.60
Abbreviations: PC, phosphocholine; PE, phosphoethanolamine; PPE, plasmenylethanolamine; Pthis abnormal recycling of brain nucleosides is ﬁnally reﬂected in al-
tered levels of other purine metabolites such as adenine, hypoxanthine
and xanthine (Table 2), in agreement with previous studies [33,34,43].
Therefore, themetabolism of purines highlights as a candidate pathway
for the search of potential markers of pathological processes occurring
in the APP/PS1 transgenic mice, as schematized in Fig. 2 (simpliﬁed
scheme of biochemical pathways related to metabolism of purines
according to the Kyoto Encyclopedia of Genes and Genomes).
The homeostasis of amino acids also suffered important impair-
ments in the brain of the APP/PS1 transgenic mice. Glutamate and
glycine were reduced in the hippocampus and the cortex, while hippo-
campal serinewas increased, denoting a dysfunctionalmodulation of N-
methyl-D-aspartate receptors (NMDA-R). In this sense, it has been
reported that NMDA receptors are decreased in different areas of the
brainwithAD [50], resulting in reduced levels of agonist neurotransmitter
amino acids such as glutamate [38,56,72], glycine [72] and D-serine;this
latter one is accompanied with increased L-serine [26,29]. By contrast,
the opposite trend was observed in the cerebellum, with increased
levels of glutamate and glycine (Table 2). This could be because
NMDA receptors have speciﬁc characteristics in the cerebellum that
make their function and modulation different from those of the
NMDA receptors in other brain areas [45]. Thereby, Balayssac et al.
found a signiﬁcant increase of the cerebellar glutamate in the APP-
Tg2576 transgenic mice [1], conﬁrming a differential dysregulation of
NMDA synapse depending on the brain region considered. Finally, the
striatum showed a signiﬁcant increase of glutamate levels, as observed
in the cerebellum, but alterations of other NMDA co-agonists (glycine
and serine) were in line with what was described for the hippocampus
and the cortex. Therefore, it could be concluded that region-speciﬁc al-
terations occur in NMDA signaling, which has not been described in any
previous metabolomic study of AD, demonstrating the speciﬁcity of
pathological mechanisms in the brain of the APP/PS1 transgenic mice.
Moreover, this abnormal content of the amino acids in the brain couldAPP/PS1 and control mice. HP, hippocampus; CT, cortex; ST, striatum; CB, cerebellum; OB,
Metabolite RT (min) Fold change
HP CT ST CB OB
Increased phospholipids
PC(20:4/20:4) 8.17 NS 1.36 NS NS NS
PC(22:6/22:4) 8.40 1.46 1.39 NS NS NS
PC(16:0/18:2) 8.57 1.61 1.80 1.55 1.80 1.43
PC(18:0/20:4) 8.86 NS 1.36 NS NS NS
PC(16:0/18:1) 8.87 NS 1.36 NS NS NS
PC(18:1/18:0) 9.19 1.36 1.33 NS NS NS
PC(18:0/22:4) 9.20 NS 1.38 NS NS NS
PC(16:0/18:0) 9.25 NS 1.45 NS NS NS
PE(20:4/20:4) 7.79 NS 1.32 NS NS NS
PE(20:4/22:4) 8.11 NS 1.50 NS 1.39 NS
PE(18:0/20:4) 8.40 NS 1.43 NS NS NS
PE(18:0/22:5) 8.58 NS 1.61 NS NS NS
PE(18:0/22:4) 8.66 1.43 1.62 NS NS NS
PPE(16:0/20:4) 8.20 NS 1.57 NS NS NS
PPE(18:0/20:4) 8.58 NS 1.42 NS NS NS
PPE(18:0/22:4) 8.85 NS 1.38 1.86 1.70 1.37
PS(18:2/18:1) 7.97 1.33 NS NS NS NS
PS(18:0/22:5) 8.27 1.55 1.38 NS NS NS
PS(18:0/20:4) 8.37 NS 1.62 NS NS NS
PS(18:1/18:0) 8.37 NS 1.28 NS NS NS
PS(18:0/20:1) 8.67 1.33 NS NS NS NS
PI(18:0/20:4) 7.94 NS 1.51 NS NS NS
PG(18:0/20:4) 7.99 1.42 1.40 NS NS NS
PG(18:1/22:4) 8.01 1.37 NS NS NS NS
SM(d18:1/16:0) 8.32 NS 1.37 NS 1.34 NS
SM(d18:1/18:0) 8.70 NS 1.60 NS 1.55 NS
S, phosphoserine; PI, phosphoinositol; PG, phosphoglycerol; and SM, sphingomyelin.
Fig. 2. Overview of hippocampal metabolomic changes in APP/PS1 mice related to purine
metabolism.
2400 R. González-Domínguez et al. / Biochimica et Biophysica Acta 1842 (2014) 2395–2402also indicate a deregulation of their transport across the blood–brain
barrier, supported by altered pyroglutamate levels. The amino acids
enter into the central nervous system by means of the sodium-
independent system L1 regulated by the γ-glutamyl cycle [39]. In this
process, the amino acids react with glutathione by the action of γ-
glutamyl transpeptidase to form γ-glutamyl amino acids, after which
enter cells are degraded to the corresponding amino acid, which liberat-
ed amolecule of pyroglutamate that is essential since it stimulates sodi-
um dependent carriers for the later removal of the deleterious amino
acids from the brain. In this context, reduced levels of pyroglutamate
have been previously reported in the AD brain [65], as observed in the
hippocampus, cortex, and striatum (Table 2). However, pyroglutamate
was increased in the cerebellum, in accordance with the speciﬁc alter-
ations observed in this region regarding glutamate and glycine. Similar
to glutamate, aspartate is an excitatory neurotransmitter that usually
presents lower concentrations in the AD brain [72]. Interestingly, the
levels of this amino acid were reduced in the brain regions where
glutamate was decreased (the hippocampus, cortex and olfactory
bulbs), pointing to correlated metabolic networks. In the same way, a
similar correlation was observed between levels of glutamate and N-
acetylaspartate (NAA). This neurochemical is a conventional biomarker
for neuronal integrity whose reduction has been traditionally associat-
ed with neural loss in Alzheimer's disease [38,56], in agreement with
our metabolomic results in the hippocampus, cortex and olfactory
bulbs (Table 2). By contrast, striatal and cerebellar levels of NAA were
higher in the APP/PS1 mice, which could be linked to increased gluta-
mate through the destabilization of Ca2+ homeostasis, as previously
described for the cerebellum of the APP-Tg2576 model [1] Taurine is
an amino acid highly concentrated in the rodent brain, with several
roles in neurotransmission, neuromodulation, osmoregulation, control
of calcium inﬂux, and cell excitability. In this study, we observed a slight
decrease in its concentration in all the brain regions investigated
(except for olfactory bulbs), in accordancewith a previousmetabolomic
study [56]. On the other hand, threonine connects the metabolism of
glycine and serine to the biosynthesis of branched-chain amino
acids, so hippocampal deﬁciency of this amino acid might be corre-
lated with perturbations in levels of glycine, serine and valine(Table 2). Finally, the reductions in histidine and its precursor,
phosphoribosyl-AMP, might suggest impaired synthesis of carnosine
and/or histamine, which are important biomolecules associated with
oxidative stress [28] and failures in neurotransmission [51] in
Alzheimer's disease.
Metabolomic signatures also revealed signiﬁcant disturbances in
energy metabolism, principally in the hippocampus and the cortex,
considering decreased levels of lactic acid, malic acid, creatinine, 2-
hydroxyglutaric acid, pyrophosphate (PPi), citric acid ad glucose-6-
phosphate (G6P), as well as increased lactose (Table 2). The decrease
of glycolytic intermediates (lactate and G6P) and increased lactose
levels support a reduced carbohydrate metabolism, while reduced cit-
rate (in all brain regions studied) and malate (only in the hippocampus
and the cortex) could be behind the perturbed Krebs cycle, in agree-
ment with previous studies [29,54,65,72]. Reduced PPi, formed by the
hydrolysis of ATP into AMP, denoted mitochondrial impairments related
to aberrations in the oxidative phosphorylation system. Moreover, the
deﬁciency of 2-hydroxyglutarate also points to disrupted mitochondrial
activity, given that this compound is a byproduct resulting from a side-
reaction of malate dehydrogenase [67]. Furthermore dyshomeostasis of
phosphocreatine system might also occur in the brain, considering the
decrease of creatinine levels observed in all the brain regions analyzed.
Therefore, it could be concluded that defects in energy metabolism are a
key hallmark in the APP/PS1 transgenic mice of AD, involving multiple
metabolic pathways such as glycolysis, TCA cycle, oxidative phosphoryla-
tion or phosphocreatine system.
Numerous alterations were also observed in the metabolism of
phospholipids, as reﬂected in Tables 2–4, which depended on the type
of fatty acid linked to the molecular moiety. Phospholipids containing
polyunsaturated fatty acids (principally docosahexaenoic acid) were
reduced in the brain samples, including phosphatidylcholines (mainly
in cortex and striatum) and minor species such as phosphatidylserines,
phosphatidylinositols and phosphatidylglycerols (in the hippocampus
and to a lesser extent the cortex). Furthermore, most phosphatidyleth-
anolamines and plasmenylethanolamines were decreased as well, prin-
cipally in the hippocampus but also affecting other areas investigated.
These deﬁcits in certain phospholipids suggest a role for oxidative stress
in the increased degradation of these compounds, in accordance with
previous studies in the brain of the transgenic mice of AD [8,24,74].
By contrast, a parallel accumulation of phospholipids containing short
chain fatty acids was also observed, especially in phosphocholines
and phosphoserines from the hippocampus and the cortex (Table 4).
Thereby, membrane destabilization processes in the APP/PS1 mice
could be related to imbalances in the levels of saturated/unsaturated
fatty acids contained in the structure of phospholipids, as recently
proposed for human AD [18]. Moreover, phospholipids derived from
docosapentaenoic and docosatetraenoic acids were also increased in
the cortex and other brain regions (Table 4), whichmight be correlated
to peroxisomal dysfunction given that these fatty acids are intermedi-
ates for the biosynthesis of DHA and other long chain polyunsaturated
fatty acids in peroxisomes. Surprisingly, aforementioned changes were
accompanied by an overall increase of arachidonoyl-derived phospho-
lipids (i.e. stearoyl-arachidonoyl phospholipids and di-arachidonoyl
phospholipids), with the cortex being the most affected region. This al-
tered fatty acid proﬁle could suggest a deregulation in the biosynthesis,
turnover and acyl chain remodeling of phospholipids, with a great
relevance in AD pathology given that the release and oxidation of
arachidonic acid from these phospholipids may produce several lipid
mediators closely associated with neuronal pathways involved in AD
[17]. Besides these changes in the phospholipid species, numerous
byproducts resulting from their degradation were found in the brain
of the APP/PS1 mice. Thereby, the hydrolysis of the ester bonds from
the phospholipids by the action of PLA2 leads to the accumulation of
the brain lysophospholipids (Table 3), not previously described to our
knowledge in the APP/PS1 mice. In addition, catabolic metabolites
glycerophosphocholine, phosphocholine and choline were elevated, in
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this degradation process, glycerol-3-phosphate and free glycerol
(Table 2). On the other hand, the biosynthesis of phosphatidylcholines
via the Kennedy cycle was also disturbed in the hippocampus, consider-
ing reductions in the precursor uridine monophosphate [10]. Further-
more the decrease of ethanolamine, involved in the turnover of
phosphatidylethanolamines, has been previously observed in the post-
mortem AD brains [13], corroborating the evidence for a membrane de-
fect in Alzheimer disease.
Alternatively, alterations in sphingomyelins (Table 4) and choles-
terol (Table 2) also emerge as a pivotal event in the dysfunctional ho-
meostasis of neural membranes in the APP/PS1 mice, suggesting
abnormalities in lipid rafts [14]. In this study, a differential regula-
tion of the brain sphingomyelins was observed depending on the
region considered and the fatty acid contained in the structure, as
described for the phospholipids. Thereby, saturated species were
increased in the hippocampus, and the unsaturated ones were de-
creased in thecortex and cerebellum. However, the most important
ﬁnding was the reduction of very long chain species in all the brain
regions investigated, in accordance with previous studies that
demonstrated elevated degradation of sphingomyelins leading to
the accumulation of ceramides containing very long chain fatty
acids [71]. On the other hand, reduced content of cholesterol has
been already described in the brains oftransgenic mice of AD [14,
74], generating serious alterations of the physicochemical structure
of the lipid rafts.
Finally, other discriminant metabolites could be considered as
markers for integrity of the central nervous system, including deﬁcits
in dopamine and urea, as well as increased myo-inositol (Table 2).
Dopamine is a neurotransmitter derived from the amino acid tyrosine,
commonly linked to Parkinson's disease, but whose reduction has
been also reported in AD subjects [62]. It is noteworthy that the higher
decrease of this neurotransmitter was found in the striatum, where
dopaminergic neurons are primarily localized. The overall reduction in
urea levels supports an abnormal homeostasis of ammonia in the
whole brain, whichmay elicit deleterious effects on the central nervous
system [15]. In this sense, the alteration of the urea cycle has been previ-
ously demonstrated on thebasis of altered levels of expression indifferent
enzymes and the corresponding genes [25], which ﬁnally results in al-
tered content of related metabolites [19,20] as found in our metabolomic
study. To conclude, the increase of myo-inositol has been traditionally
proposed as amarker for osmotic stress or astrogliosis, frequently detect-
ed by 1HNMR investigations [16,73].
In conclusion, this study shows that levels of numerous metabolites
are altered in the brain from the APP/PS1 mice, such as phospholipids,
amino acids or nucleotides among others, affecting primarily the hip-
pocampus and the cortex, and to a lesser extent the cerebellum, stria-
tum and olfactory bulbs. These metabolic alterations enabled the
elucidation of underlying pathological mechanisms in the APP/PS1
mice, including the abnormal metabolism of purines, bioenergetic fail-
ures, dyshomeostasis of amino acids and disturbances in membrane
lipids. Furthermore, it is noteworthy to mention the region-speciﬁcity
of processes occurring in the brain of the APP/PS1 mice. As a future
plan, a second validation phase should be performed on a larger num-
ber of samples using a targeted approach, more sensitive and selective,
in order to conﬁrm our ﬁndings and demonstrate the potential of these
discriminant metabolites as potential biomarkers for diagnosis.Acknowledgements
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